Cationic Diclofenac Lipid Nanoemulsion for Improved Oral Bioavailability: Preparation, Characterization and In Vivo Evaluation
DOI:
https://doi.org/10.37285/ijpsn.2015.8.2.10Abstract
Cationic nanoemulsions were reported to have increased bioavailability. The aim of present study was to prepare a cationic lipid nanoemulsion of diclofenac acid (LNEs) for improved oral bioavailability to treat arthritic conditions. The LNEs of diclofenac acid were prepared by using soya bean oil, egg lecithin, cholesterol and stearylamine. Stearylamine was used as positive charge inducer. The LNEs were processed by homogenization and ultrasonication. The formulation composition was selected based on earlier reports. The LNEs were characterized for size and zeta potential. The physical stability of LNEs was studied using autoclaving, centrifugal, desorption (dilution effect) stresses and on storage. The total drug content and entrapment efficiency were determined using HPLC. During in vivo studies in Wistar rats, the pharmacokinetic parameters of LNEs were compared with a prepared diclofenac suspension in sodium CMC mucilage. The selected formulations, F1, F2 and F3, were relatively stable during centrifugal stress, dilution stress and on storage. The drug content was found to be 2.38 ± 1.70 mg/ml for F1, 2.30 ± 0.82 mg/ml for F2, and 2.45 ± 0.66 mg/ml for F3. The entrapment efficiencies were 97.83 ± 0.53%, 97.87 ± 1.22% and 98.25 ± 0.21% for F1, F2 and F3 respectively. The cumulative percentage drug release from F1, F2 and F3 showed more release in pH 6.8 phosphate buffer than in pH 1.2 HCl. During oral bioavailability studies, the LNEs showed higher serum concentrations than a suspension. The relative bioavailability of the LNE formulations F1, F2 and F3 were found to be 2.35, 2.94 and 6.28 times that of F4 suspension and were statistically significant. Of all, the cationic lipid nanoemulsion (F3) was superior in improving bioavailability, when compared with plain emulsion (F1) and cholesterol containing LNE (F2). The study helps in designing the cationic oral nanoemulsions to improve the oral bioavailability of diclofenac.
Downloads
Metrics
Keywords:
Lipid nanoemulsion, Diclofenac acid, Oral bioavailability, Cationic emulsions, Anti-inflammatory drug
Downloads
Published
How to Cite
Issue
Section
References
Doreen MS, Boardman P L, Fowler PD and Poole PD (1978). Diclofenac (Voltarol) in Rheumatoid Arthritis: A report of a Double Blind Trial. Rheumatol. 17: 95-102.
Gershanik T and Benita S (1996). Positively Charged Self-Emulsifying oil Formulation for Improving oral Bioavailability of Progesterone. Pharm Dev and Technol. 1(2): 147-157.
Hagigit T, Abdulrazik M, Orucov F, Valamanesh F, Hagedorn M, Lambert G, Behar-Cohen F and Benita, S (2010). Topical and Intravitreous Administration of Cationic Nanoemulsions to Deliver Antisense Oligonucleotides Directed towards VEGF KDR Receptors to the Eye. J Control Release. 145(3): 297-305.
Hagigit T, Abdulrazik M, Valamanesh F, Behar-Cohen F and Benita S (2012). Ocular Antisense Oligonucleotide Delivery by Cationic Nanoemulsion for Improved Treatment of Ocular Neovascu-larization: An in-vivo Study in Rats and Mice. J Control Release. 160(2): 225-31.
Kendall MJ, Thornhill DP and Willis JV (1979). Factors affecting the Pharmacokinetics of Diclofenac Sodium (Voltarol). Rheumatol. Rehabilit. 2: 38-46.
Khazaeinia T and Jamali FA (2003). Comparison of Gastro Intestinal Permeability Induced by Diclofenac Phospholipid Complex with Diclofenac Acid and its Sodium Salt. J. Pharm Pharm.Sci. 6(3): 352-359.
Krishna G, Wood GC and Sheth BB (1998). Improving Emulsification Efficacy of Lecithin by Formulation Design. I. effect of adding Secondary Surfactant. PDA J. Pharm Sci. Technol. 52: 331-336.
Kurowski M (1988). Pharmacokinetics and Biological Activity of Diclofenac Preparations following Intramuscular Injection of 75 mg and oral Administration of 150 mg Of Active Drug. Z Rheumatol. 47: 37-42.
Lallemand F, Daull P, Benita S, Buggage R and Garrigue JS (2012). Successfully Improving ocular Drug Delivery using the Cationic Nanoemulsion, Novasorb. J Drug Deliv. doi: 10.1155/2012/ 604204.
Lundberg BB, Mortimer BC and Redgrave TG (1996). Lipid Nanoemulsion containing Amphipathic Poly Ethylene Glycol for use as Drug Carriers with Prolonged Circulation Time. Int. J. Pharm. 134:119-127.
Lundberg BB. (1997). A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral Administration of Paclitaxel (Taxol). J. Pharm. Pharmacol. 49 (1):16-21.
Menasse R, Hedwall PR., Kraetz J, Pericin C, Riesterer L, Sallmann A, Ziel R and Jaques R (1978). Pharmacological Properties of Diclofenac Sodium and its Metabolites. Scand. J. Rheumatol. 22: 5–16.
Meyer S, Berrut S, Goodenough TIJ, Rajendram VS, Pinfield VJ and Povey MJW (2006). A Comparative Study of Ultrasound and Laser Light Diffraction Techniques for Particle Size Determination in Dairy Beverages. Meas. Sci. Technol. 17: 289-297.
Prabhakar K, Muzammil Afzal Syed, Surendar G and Kishan V (2012). Albumin Coupled Lipid Nanoemulsions of Diclofenac for Targeted Delivery to Inflammation. Nanomedicine: Nanotechnology, Biology and Medicine. 8: 1162-1171.
Ramesh T, Sane Rajan S, Samant Vinay C and Nayak (1987). High Performance Liquid Chromatographic Determination of Diclofenac Sodium from Pharmaceutical Preparation. Drug Dev. Ind. Pharm. 13(7): 1307 - 1314.
Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G (2006). Celecoxib Verses Naproxen and Diclofenac in Osteoarthritis Patients: Success-I Study. Am. J. Med. 119 (3): 255-66.
Srividya R, Prabhakar K and Kishan V (2012). Formulation and Pharmacokinetics of Diclofenac Lipid Nanoemulsions for Parenteral Application. PDA. J. Pharm. Sci Technol. 66(1): 28-37.
Varshika E, Prabakar K and Kishan V (2009). Preparation, Characterization and In Vivo Pharmacodynamic Evaluation of Parenteral Diclofenac Lipid Nanoemulsions. PDA. J Pharm Sci Tech. 63(5): 380-9.
Willis J, Kendall MJ, Flinn RM, Thornhill DP and Welling PG (1979). The Pharmacokinetics of Diclofenac Sodium Following Intravenous and oral Administration. Eur. J. Clin Pharmacol. 16: 405-410.
